S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Humanigen (NASDAQ:HGEN) Now Covered by JPMorgan Chase & Co.

Tuesday, February 23, 2021 | MarketBeat

Investment analysts at JPMorgan Chase & Co. initiated coverage on shares of Humanigen (NASDAQ:HGEN) in a report issued on Tuesday, The Fly reports. The brokerage set a "neutral" rating on the stock.

HGEN has been the topic of a number of other research reports. Zacks Investment Research lowered Humanigen from a "hold" rating to a "sell" rating in a report on Friday, January 22nd. Jefferies Financial Group assumed coverage on Humanigen in a report on Tuesday, December 22nd. They issued a "buy" rating and a $27.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 price objective (up previously from $31.00) on shares of Humanigen in a report on Friday, November 6th. Finally, National Securities assumed coverage on Humanigen in a report on Wednesday, December 23rd. They issued a "buy" rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company's stock. The company presently has a consensus rating of "Buy" and an average price target of $29.20.

NASDAQ HGEN opened at $21.52 on Tuesday. Humanigen has a 52-week low of $1.64 and a 52-week high of $33.95. The business's 50-day moving average price is $19.31 and its 200 day moving average price is $14.37.

In other news, major shareholder Bay Ltd. Nomis sold 25,000 shares of Humanigen stock in a transaction that occurred on Monday, December 21st. The shares were sold at an average price of $19.46, for a total transaction of $486,500.00. Following the completion of the sale, the insider now directly owns 6,469,733 shares in the company, valued at approximately $125,901,004.18. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 454,269 shares of company stock valued at $9,017,992. Insiders own 37.50% of the company's stock.

Several hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. acquired a new position in shares of Humanigen during the 4th quarter worth approximately $3,270,000. Virtus ETF Advisers LLC acquired a new position in shares of Humanigen during the 4th quarter worth approximately $432,000. Northern Trust Corp acquired a new position in shares of Humanigen during the 4th quarter worth approximately $1,295,000. Citigroup Inc. acquired a new position in shares of Humanigen during the 4th quarter worth approximately $337,000. Finally, Wells Fargo & Company MN acquired a new position in shares of Humanigen during the 4th quarter worth approximately $426,000. Institutional investors own 30.18% of the company's stock.

About Humanigen

Humanigen, Inc, a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia.

Further Reading: Stocks Increasing Dividends

The Fly

Analyst Recommendations for Humanigen (NASDAQ:HGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]


7 Lithium Stocks That Will Power the Electric Vehicle Boom

Demand for lithium is set to increase exponentially in the next few years. In fact, according to Statista, demand for lithium may very well double to 820,000 tons in that time. Some of that demand will come from companies that are manufacturing the batteries that we use every day. For example, lithium is an essential component of the batteries that power our mobile devices.

But the real growth will come as the United States goes all-in on electric vehicles (EVs). The Biden administration recently announced plans to have the U.S. government’s fleet of over 600,000 vehicles converted to EVs.

And as you’re aware, EV stocks are in a bubble of some sort at the moment. Some of that is due to the increasing number of companies that went public last year. However, as investors are beginning to realize, not all of these companies will be the next Tesla. In fact, some of these companies may never be successful at bringing an EV to market, at least not at the scale that will be required.

The ones that do make it will need lithium and lots of it. To help you sift through the best lithium stocks to buy, we’ve put together this special presentation.

View the "7 Lithium Stocks That Will Power the Electric Vehicle Boom".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.